Nordicus Partners CORP

Nordicus Partners Corporation announced the immediate resignation of Andrew J. Ritter from its Board of Directors and its committees, effective July 7, 2026.

Nordicus Partners Corporation announced the establishment of its Audit, Compensation, and Nominating Committees, along with the adoption of their respective charters.

Nordicus Partners Corporation announced the completion of a private offering, issuing 131,000 restricted common shares to ten investors at $2.75 per share, raising $360,250.

Nordicus Partners Corporation completed a private offering, issuing 416,000 restricted common shares to eight investors at $2.75 per share, raising $1.14 million.

Nordicus Partners Corporation completed a private offering, issuing 1,057,500 restricted common shares to 54 investors at $1.90 per share, raising approximately $2 million.

Nordicus Partners Corporation has furnished independent valuation reports for its wholly-owned subsidiaries, Orocidin A/S and Bio-Convert A/S, to analysts and investors.

Nordicus Partners reports increased net losses for the nine months ended December 31, 2025, despite significant R&D progress in its biotech portfolio and a substantial cash infusion from financing activities.

Nordicus Partners Corporation reported a significant increase in net loss for the six months ended September 30, 2025, as it continues to expand its preclinical biotechnology portfolio and address going concern issues.

Nordicus Partners Corporation reported a significant increase in net loss for the quarter ended June 30, 2025, driven by higher operating expenses and investment losses, despite positive preclinical developments for its portfolio companies.

Nordicus Partners Corporation files its quarterly report, highlighting acquisitions and financial results for the period ending December 31, 2024.

Nordicus Partners Corporation reported a significant increase in net loss for the second quarter of 2025, driven by increased operating expenses and the impact of recent acquisitions.

Nordicus Partners Corporation reported a net loss of $258,169 for the quarter ended June 30, 2024, primarily due to increased operating expenses and the acquisition of Orocidin A/S.

Nordicus Partners Corporation files its annual report for the fiscal year ended March 31, 2026, detailing its preclinical biotech developments, acquisitions, and financial performance.

Nordicus Partners Corporation, a U.S. business accelerator for Nordic life sciences companies, reported substantial expansion of its preclinical biotechnology portfolio through key acquisitions and promising drug development milestones, alongside a significant increase in operating expenses and net losses for the fiscal year ended March 31, 2025.

Nordicus Partners Corporation reported its first revenue and made strategic acquisitions in the fiscal year ending March 31, 2024, while also addressing going concern issues.

Nordicus Partners Corp CEO Henrik Rouf reported multiple sales of common stock, significantly reducing his beneficial ownership following a 1-for-10 reverse stock split.

GK Partners ApS, a 10% owner and director of Nordicus Partners Corp, reported a net decrease of 100,540 shares in its beneficial ownership through various transactions.

AC Nordic ApS, a 10% owner and director of Nordicus Partners Corp, reported multiple transactions in NORD common stock, resulting in a net decrease in beneficial ownership.

ABCHill Holding ApS clarifies its beneficial ownership of 5.33% in Nordicus Partners Corporation, correcting an inadvertently filed Form 4.

Nordicus Partners Corp. has reported several share transactions, including acquisitions of Bio-Convert ApS and Orocidin A/S, along with warrant exercises.

Nordicus Partners Corporation acquired Bio-Convert ApS through a share exchange on November 12, 2024.

Nordicus Partners Corporation is implementing a 1-for-10 reverse stock split and adopting a new 2024 Stock Incentive Plan, approved by the board and major stockholders.

Nordicus Partners Corporation is implementing a 1-for-10 reverse stock split and adopting a new stock incentive plan, approved by a majority of voting stockholders.

Nordicus Partners Corporation has filed an amendment to its S-1 registration statement to include an opinion of counsel and auditor consent, related to the resale of 16,190,911 shares of common stock.

Nordicus Partners Corporation has filed a registration statement for the resale of 16,190,911 shares of its common stock by existing shareholders.

GK Partners ApS has disclosed significant adjustments to its beneficial ownership in Nordicus Partners Corp, including warrant exercises and private transactions, now holding 17.71% of common stock.

ABCHill Holding ApS reported a 5.97% beneficial ownership in Nordicus Partners Corp, detailing a series of share acquisitions and dispositions for asset diversification and liquidity.

AC Nordic ApS has increased its beneficial ownership in Nordicus Partners Corp to 17.42% through a series of private transactions and acquisitions from the company.